<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975594</url>
  </required_header>
  <id_info>
    <org_study_id>SIR-2021/05-UKL</org_study_id>
    <nct_id>NCT04975594</nct_id>
  </id_info>
  <brief_title>Statin-Intolerance Registry</brief_title>
  <acronym>SIR</acronym>
  <official_title>Statin-Intolerance Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Statin-Intolerance Registry will characterize the patient population suffering from&#xD;
      statin-intolerance which is a frequent but incompletely understood patient condition with&#xD;
      important clinical implications for atherosclerotic cardiovascular disease (ASCVD)&#xD;
      prevention.&#xD;
&#xD;
      Patients will be systematically and prospectively included and followed by the registry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional registry based on routine clinical practice will collect data under&#xD;
      real-life conditions. The treatment of patients will not be changed by this study.&#xD;
&#xD;
      Data on patient characteristics and the treatment history will be collected via&#xD;
      questionnaires at study entree. Yearly follow up visits will re-assess the baseline&#xD;
      parameters and document cardiovascular events.&#xD;
&#xD;
      The data will be analyzed using descriptive statistics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment adjustments</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LDL cholesterol level</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>by EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of muscle symptoms over time that initially lead to discontinuation of statin therapy</measure>
    <time_frame>3 years</time_frame>
    <description>based on the &quot;Statin-Associated Muscle Symptom Clinical Index&quot; (SAMS-CI)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Dyslipidemias</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with statin-intolerance&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with dyslipidemia and statin intolerance, defined as:&#xD;
&#xD;
             Use of 2 or more statins and intolerance of these drugs in any dose or inability to&#xD;
             tolerate dosage increasement beyond a maximum weekly dose of 70 mg atorvastatin, 140&#xD;
             mg Simvastatin, pravastatin, or lovastatin, 35 mg rosuvastatin, 280 mg of Fluvastatin&#xD;
             and symptoms improve or disappear when statin is reduced in dosage or discontinued&#xD;
&#xD;
          2. Participants are ≧ 18 years old&#xD;
&#xD;
          3. Written declaration of consent is available&#xD;
&#xD;
          4. The patient is cognitively, linguistically and organizationally capable to meet the&#xD;
             study requirements. The possibility of 1 year follow-up is very likely.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any experimental or investigational drugs within 30 days prior to screening.&#xD;
&#xD;
          2. An employee or contractor of the facility conducting the study, or a family member of&#xD;
             the principal investigator, co-Investigator, or sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Laufs</last_name>
    <role>Study Director</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulina Stürzebecher</last_name>
    <phone>0049 341 97 11535</phone>
    <email>Paulina.stuerzebecher@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uniklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulina Stürzebecher, MD</last_name>
      <email>paulina.stuerzebecher@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Ulrich Laufs</investigator_full_name>
    <investigator_title>Prof. Dr. med</investigator_title>
  </responsible_party>
  <keyword>Statins</keyword>
  <keyword>Muscle symptoms</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

